Rxsight, INC Form 4 insider transactions

Eric Weinberg, See remarks of RxSight, Inc., reported multiple transactions in common stock on September 15, 2026.

Mark Wilterding, Chief Financial Officer of RxSight, Inc., reported multiple transactions in common stock on September 5, 2026.

Eric Weinberg, See remarks of RxSight, Inc., reported multiple transactions in common stock on September 5, 2026.

Ronald M Kurtz, Chief Medical Officer of RxSight, Inc., reported multiple transactions in common stock on September 5, 2026.

Ilya Goldshleger, Chief Operating Officer of RxSight, Inc., reported multiple transactions in common stock on September 5, 2026.

Ronald M Kurtz, Chief Medical Officer of RxSight, Inc., sold 5,100 shares of common stock on August 31, 2026 for $6.96 per share.

Mark Wilterding, Chief Financial Officer of RxSight, Inc., sold 7,765 shares of common stock on August 31, 2026 for $6.96 per share.

Ilya Goldshleger, Chief Operating Officer of RxSight, Inc., sold 2,041 shares of common stock on August 31, 2026 for $6.96 per share.

Eric Weinberg, See remarks of RxSight, Inc., sold 2,041 shares of common stock on August 31, 2026 for $6.96 per share.

Aziz Mottiwala, President and CEO and a Director of RxSight, Inc., reported multiple transactions in common stock on July 24, 2026.

Robert Keith Warner, a Director at RxSight, Inc., acquired 37,037 shares of common stock on June 17, 2026, as per a Form 4 filing.

RxSight, Inc. reports that Director Robert J. Palmisano acquired 37,037 shares of common stock on June 17, 2026, as part of his compensation.

RxSight, Inc. Director Shweta Maniar acquired 37,037 shares of common stock through restricted stock units.

Director Tamara Fountain acquired 37,037 shares of common stock in RxSight, Inc. on June 17, 2026, as detailed in a Form 4 filing.

William J. Link, PhD, a Director at RxSight, Inc., has acquired 37,037 shares of common stock, increasing his beneficial ownership.

RxSight, Inc. Director Jesse Anderson Corley filed a Form 4 reporting the acquisition of 37,037 shares of common stock.

RxSight, Inc. Director Raymond W. Cohen acquired 30,864 shares of common stock on June 17, 2026, as part of an equity award.

Juliet Bakker, a Director at RxSight, Inc., has filed a Form 4 detailing transactions related to her beneficial ownership of company stock.

Julie Andrews, a Director at RxSight, Inc., has reported a transaction involving the acquisition of 37,037 shares of common stock.

RxSight Chief Operating Officer Ilya Goldshleger exercised options to acquire 12,489 shares of common stock.

RxSight's Chief Financial Officer, Mark Wilterding, reported the vesting of 20,441 Restricted Stock Units and a subsequent sale of 8,068 shares for tax withholding purposes.

RxSight Chief Customer Officer Scott Gaines reported recent acquisitions and dispositions of common stock and restricted stock units, including new RSU grants and vesting events.

RxSight, Inc. Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units, vesting over several years.

RxSight's Chief Business Development Officer, Eric Weinberg, was granted 32,218 restricted stock units, vesting over several years.

RxSight, Inc. President and CEO, Ronald M. Kurtz, MD, was granted 80,545 restricted stock units, vesting over several years.

RxSight, Inc. Chief Financial Officer Mark Wilterding received grants of 258,770 stock options and 163,528 restricted stock units, aligning his interests with long-term shareholder value.

RxSight's Co-President and COO, Ilya Goldshleger, exercised a significant number of stock options, acquiring common stock and increasing his direct beneficial ownership.

RxSight, Inc. Director Raymond W. Cohen was granted 35,668 restricted stock units (RSUs) effective July 31, 2025.

RxSight, Inc. Director William J. Link, Ph.D., was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of his compensation, aligning his interests with shareholders.

RxSight, Inc. Director Tamara Fountain was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of her compensation, aligning her interests with shareholders.